Did the H1N1 Vaccine Reduce the Risk of Admission with Influenza and Pneumonia during the Pandemic?

The extent to which A(H1N1)pdm09 influenza vaccines prevented hospital admissions with pneumonia and influenza (P&I) during the 2009 pandemic remains poorly understood. We evaluated the effectiveness of the A(H1N1)pdm09 and seasonal influenza vaccines (TIV) used during the 2009 mass vaccination...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2015-11, Vol.10 (11), p.e0142754-e0142754
Main Authors: Mahmud, Salaheddin M, Bozat-Emre, Songul, Hammond, Gregory, Elliott, Lawrence, Van Caeseele, Paul
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic
Adolescent
Adult
Adults
Age
Aged
Care and treatment
Case-Control Studies
Child
Child, Preschool
Children
Dosage and administration
Female
Health risks
Health sciences
Hospitalization
Hospitals
Humans
Immunization
Immunization Programs
Infant
Influenza
Influenza A Virus, H1N1 Subtype - immunology
Influenza vaccines
Influenza Vaccines - immunology
Influenza, Human - epidemiology
Influenza, Human - prevention & control
Laboratories
Male
Manitoba
Middle Aged
Older people
Pandemics
Patient Admission
Pneumonia
Pneumonia - epidemiology
Pneumonia - prevention & control
Registries
Risk
Risk factors
Risk reduction
Swine flu
Vaccines
Womens health
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The extent to which A(H1N1)pdm09 influenza vaccines prevented hospital admissions with pneumonia and influenza (P&I) during the 2009 pandemic remains poorly understood. We evaluated the effectiveness of the A(H1N1)pdm09 and seasonal influenza vaccines (TIV) used during the 2009 mass vaccination campaign in Manitoba (Canada) in preventing P&I hospitalization. A population-based record-linkage nested case-control study. Cases (N = 1,812) were persons hospitalized with influenza (ICD-10:J09-J11) or pneumonia (ICD-10:J12-J18) during the study period. Age-, gender- and area of residence-matched controls (N = 7,915) were randomly sampled from Manitoba's Population Registry. Information on receipt of A(H1N1)pdm09 vaccine and TIV was obtained from the Manitoba Immunization Monitoring System, a province-wide vaccine registry. Overall, the adjuvanted A(H1N1)pdm09 vaccine was 27% (95%CI 13-39%) effective against P&I hospitalization ≥ 14 days following administration. Effectiveness seemed lower among older (≥ 65 years) adults (10%; -16-30%), particularly when compared to under-5 children (58%; 30-75%). The number-needed-to-vaccinate to prevent 1 P&I admission was lowest among
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0142754